Mycophenolic Acid (Mycophenilic Acid)
Brand Names: Mycophenolic Acid
Methodology & AI Transparency ⓘ
Mycophenolic Acid (Mycophenilic Acid) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Mycophenolic Acid is a prescription brand-name antimetabolite immunosuppressant product delivering active pharmaceutical ingredient Mycophenilic Acid, registered by Archis Pharma LLC under NDC 72819-155, 72819-156.
- 2 Real-world patient consensus: Mycophenolic Acid links directly to generic Mycophenilic Acid under FDA SPL 2026-07-01 (NDC 72819-155).
- 3 Typical cash cost range: Dispensing cost comparison spans $15.59 mail/discount cash up to $41.31 uninsured retail (federal NADAC $0.0985).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Mycophenolic Acid (Mycophenilic Acid) include nausea (8.9%), headache (7.3%), dizziness (5.2%).
Ask our AI Specialists anything about Mycophenolic Acid (Mycophenilic Acid)
Mycophenolic Acid (Mycophenilic Acid) Mechanism, CYP450 Pathways & DailyMed Monograph
Mycophenolic Acid is a prescription brand-name antimetabolite immunosuppressant product delivering active pharmaceutical ingredient Mycophenilic Acid, registered by Archis Pharma LLC under NDC 72819-155, 72819-156. Updated in FDA DailyMed SPL on 2026-07-01, this branded presentation (180 mg/1 Tablet, Delayed Release; 360 mg/1 Tablet, Delayed Release) supports FDA-labeled antimetabolite immunosuppressant clinical management protocols.
Pharmacologically, Mycophenolic Acid derives its clinical activity from Mycophenilic Acid, a antimetabolite immunosuppressant molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (180 mg/1 Tablet, Delayed Release; 360 mg/1 Tablet, Delayed Release; registered by Archis Pharma LLC) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Mycophenilic Acid (CMS NADAC $0.0985/unit vs. $41.31 retail).
Clinical clearance of Mycophenolic Acid (Mycophenilic Acid) (Antimetabolite Immunosuppressant) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (mycophenolic acid (mycophenilic acid)) with a Biphasic clearance with 8–19 hr terminal t½ under Mycophenolic Acid (Mycophenilic Acid) maintenance half-life; patients absorbing at Systemic oral bioavailability of roughly 62%–74% following first-pass transit bioavailability typically observe target onset around initial pharmacodynamic onset within 1–4 hrs (peak cmax) for mycophenolic acid (mycophenilic acid).
FDA clinical labeling for Mycophenolic Acid (Mycophenilic Acid) restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to mycophenilic acid or mycophenolic acid (mycophenilic acid) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 mycophenolic acid (mycophenilic acid) spl across 180 mg/1 Tablet, Delayed Release, 360 mg/1 Tablet, Delayed Release, with self-reported patient tracking dominated by nausea (8.9% of reports), headache (7.3% of reports), fatigue (5.5% of reports).
Avoid overlapping antimetabolite immunosuppressant prescriptions alongside Mycophenolic Acid (Mycophenilic Acid) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Mycophenolic Acid (Mycophenilic Acid) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Mycophenilic Acid or Mycophenolic Acid (Mycophenilic Acid) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Mycophenolic Acid (Mycophenilic Acid) SPL
Logged Side-Effect Incidence (13 Reports)
Mycophenolic Acid (Mycophenilic Acid) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mycophenolic Acid (Mycophenilic Acid))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney Similar effects of belimumab on biomarker outcomes were observed within the induction groups. Kidney international • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42055319 ↗ |
| Can This Approach Help? Inside the Latest Research on Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Among patients with SSc-ILD in the SENSCIS trial, PBC modules involved in myeloid lineage were associated with. Arthritis & rheumatology (Hoboken, N.J.) • 2025-12-15 • Phase III Randomized Trial | N = 120 | 88/100 | PMID 40420438 ↗ |
| Can This Approach Help? Inside the Latest Research on A composite endpoint for systemic sclerosis-associated interstitial lung disease: The results of this post-hoc analysis provide further evidence that a composite endpoint comprised of physiological, radiological and patient-reported outcomes is a promising endpoint for SSc-ILD trials. Respiratory research • 2025-11-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41316297 ↗ |
Mycophenolic Acid (Mycophenilic Acid) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0985/unit (~$2.96/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.31 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $15.59 / mo | View logs ↓ |
Mycophenolic Acid (Mycophenilic Acid) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mycophenolic Acid (Mycophenilic Acid) RxNorm Concept ID | RXN-B72819155 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0985 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.31 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.59 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mycophenolic Acid (Mycophenilic Acid) Patient Community, Cohort Filters & Dosage Logs
Deterministic Mycophenolic Acid (Mycophenilic Acid) reference combining NIH RxNorm (RXN-B72819155), Medicaid NADAC ($0.0985/unit), and anonymous cohort outcomes (91% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mycophenolic Acid (Mycophenilic Acid) community threads and patient logs by age, biological sex, dosage, and treatment duration.